FrancophonIA/ELRC3.0 huggingface dataset:
English: As for every medicine, the company provided studies on the quality of Ambrisentan Mylan.
Estonian: Nagu iga ravimi korral, esitas ettevõte Ambrisentan Mylani kvaliteedi uuringud.
English: Other information about Ambrisentan Mylan
Estonian: Muu teave Ambrisentan Mylani kohta
English: Ambrisentan Mylan contains the active substance ambrisentan and is a ‘generic medicine'.
Estonian: Ambrisentan Mylan sisaldab toimeainena ambrisentaani ja on geneeriline ravim.
English: By blocking the effect of endothelin, Ambrisentan Mylan prevents the vessels becoming too narrow helping to lower the blood pressure and improving symptoms.
Estonian: Endoteliini toime blokeerimisega võimaldab Ambrisentan Mylan veresoontel laieneda, mis aitab alandada vererõhku ja leevendada sümptomeid.
English: It causes high blood pressure in the vessels taking blood from the heart to the lungs and reduces the
Estonian: See põhjustab kõrget vererõhku veresoontes, mis viivad verd südamest kopsudesse, ja vähendab verevoolu kopsudes.
English: Ambrisentan Mylan is a medicine that is used alone or combined with other medicines to treat adults with pulmonary arterial hypertension (PAH).
Estonian: Ambrisentan Mylanit kasutatakse ainuravimina või koos muude ravimitega pulmonaalse arteriaalse hüpertensiooni raviks täiskasvanutel.
English: PAH is abnormally high blood pressure in the arteries of the lungs.
Estonian: Pulmonaalne arteriaalne hüpertensioon on kopsuarterite ebanormaalselt kõrge vererõhk.
English: How has Ambrisentan Mylan been studied?
Estonian: Kuidas Ambrisentan Mylanit uuriti?
English: As a result, the amount of oxygen that can get into the blood in the lungs is reduced, making physical activity more difficult.
Estonian: Kõrge vererõhk vähendab kopsudes verre sattuva hapniku kogust, mis raskendab kehalist tegevust.
English: An overview of Ambrisentan Mylan and why it is authorised in the EU
Estonian: Ülevaade ravimist Ambrisentan Mylan ja ELis müügiloa väljastamise põhjendus
English: The active substance in Ambrisentan Mylan, ambrisentan, blocks the receptors (targets) for a hormone called endothelin, which causes blood vessels to become narrow.
Estonian: Ambrisentan Mylani toimeaine ambrisentaan blokeerib veresoonte kokkutõmbumist põhjustava hormooni endoteliini retseptoreid.
English: Ambrisentan Mylan can only be obtained with a prescription and treatment must be started by a doctor who has experience in the treatment of PAH.
Estonian: Ambrisentan Mylan on retseptiravim ja ravi peab alustama pulmonaalse arteriaalse hüpertensiooni ravis kogenud arst.
English: Ambrisentan Mylan is effective in PAH with no identified cause and in PAH caused by connective tissue disease.
Estonian: On tõendatud, et Ambrisentan Mylan on efektiivne teadmata põhjusega pulmonaalse arteriaalse hüpertensiooni korral ning sidekoehaigusest põhjustatud pulmonaalse arteriaalse hüpertensiooni korral.
English: How is Ambrisentan Mylan used?
Estonian: Kuidas Ambrisentan Mylanit kasutatakse?
English: PAH is a debilitating disease where there is severe narrowing of the blood vessels of the lungs.
Estonian: Pulmonaalne arteriaalne hüpertensioon on invaliidistav haigus, mille korral kopsude veresooned ahenevad tugevasti.
English: How does Ambrisentan Mylan work?
Estonian: Kuidas Ambrisentan Mylan toimib?
English: The dose is increased to 10 mg daily when the medicine is used with tadalafil (another medicine for PAH).
Estonian: Kui ravimit kasutatakse koos tadalafiiliga (samuti pulmonaalse arteriaalse hüpertensiooni ravim), suurendatakse annust kuni 10 mg.
English: What are the benefits and risks of Ambrisentan Mylan?
Estonian: Milles seisneb Ambrisentan Mylani kasulikkus ja mis riskid ravimiga kaasnevad?
English: 11 October 2019
Estonian: 11. oktoober 2019
English: The European Commission issued a decision on 11 October 2019.
Estonian: Euroopa Komisjon tegi otsuse 11. oktoobril 2019.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/129)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/129) tulemused
English: What is paromomycin?
Estonian: Mis on paromomütsiin?
English: Why were veterinary medicines containing paromomycin reviewed?
Estonian: Miks paromomütsiini sisaldavad veterinaarravimid läbi vaadati?
English: Therefore, the CVMP recommended suspending the marketing authorisations for these veterinary medicines until adequate data are available.
Estonian: Seepärast soovitas veterinaarravimite komitee peatada nende ravimite müügiload, kuni piisavad andmed on kättesaadavad.
English: The Committee also noted the possibility that inappropriate doses could lead to bacterial resistance.
Estonian: Komitee pidas ka võimalikuks, et ebasobivad annused võivad põhjustada bakteriresistentsust.
English: The Belgian authority noted that there were different approved uses, dose schedules and withdrawal periods across the EU.
Estonian: Belgia ravimiamet märkis, et ELis on erinevad heakskiidetud näidustused, annustamisskeemid ja keeluajad.
English: The withdrawal period is the minimum time that has to elapse before an animal treated with a medicine can be slaughtered and its meat or other animal derived products may be used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav minimaalne aeg, mille jooksul ei tohi looma tappa ega tema liha või muid loomseid saadusi inimtoiduks tarvitada.
English: On 25 September 2018, the Belgian medicines authority requested that the CVMP review all available data on paromomycin's effectiveness and residue depletion (how long a medicine takes to fall below maximum residue limits (MRLs) in the animal's body).
Estonian: 25. septembril 2018 esitas Belgia ravimiamet taotluse, et veterinaarravimite komitee vaataks läbi kõik kättesaadavad andmed paromomütsiini efektiivsuse ja jääkide ammendumise kohta (aeg, kuni ravimi sisaldus looma organismis väheneb alla jääkide piirnormi).
English: On 18 July 2019, the European Medicines Agency recommended suspending the marketing authorisations for paromomycin antibiotics given to pigs by injection into a muscle.
Estonian: 18. juulil 2019 soovitas Euroopa Ravimiamet peatada sigadele intramuskulaarse süstena manustatavate paromomütsiinantibiootikumide müügiload.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of these medicines do not outweigh their risks because of inadequate data supporting their use in pigs and the possibility of bacterial resistance.
Estonian: Ameti veterinaarravimite komitee järeldas, et nende ravimite kasulikkus ei ole suurem kui nendega kaasnevad riskid, sest ravimite kasutamise kohta sigadel ja bakteriresistentsuse tekke võimalikkuse kohta ei ole piisavaid andmeid.
English: Paromomycin is an aminoglycoside antibiotic used to treat a wide range of bacterial infections and is given to pigs by injection into a muscle.
Estonian: Paromomütsiin on mitmesuguste bakterinfektsioonide raviks kasutatav aminoglükosiidantibiootikum, mida manustatakse sigadele intramuskulaarse süstena.
English: The Committee based its opinion on the lack of adequate data on how effective these medicines are and residue depletion data.
Estonian: Komitee tugines oma arvamuses piisavate andmete puudumisele ravimi efektiivsuse ja ravimijääkide ammendumise kohta.
English: Questions and answers on suspension of marketing authorisations for injectable veterinary medicines containing paromomycin given to pigs
Estonian: Sigadel kasutatavate paromomütsiini sisaldavate süstitavate veterinaarravimite müügilubade peatamise teave
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of veterinary medicines containing paromomycin given to pigs by injection into the muscle do not outweigh their risks.
Estonian: Veterinaarravimite komitee järeldas praegu kättesaadavate andmete ja komitees toimunud teaduslike arutelude põhjal, et sigadele intramuskulaarse süstena manustatavate paromomütsiini sisaldavate
English: These included data from companies and published literature.
Estonian: Veterinaarravimite komitee vaatas läbi kättesaadavad efektiivsuse ja jääkide ammendumise andmed, sealhulgas andmed ettevõtetelt ja avaldatud kirjandusest.
English: 08019 - Barcelona Spain
Estonian: 08019 - Barcelona Hispaania
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Estonian: Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside, taotlejate, müügiloa hoidjate loetelu liikmesriikides
English: 1045 Budapest, Hungary
Estonian: 1045 Budapest, Ungari
English: Evropská 846/176a 160 00 Praha 6
Estonian: Evropská 846/176a 160 00 Praha 6 Tsehhi
English: GR-Greece
Estonian: GR- Kreeka
English: Culliganlaan, 1C 1831 Diegem
Estonian: Culliganlaan, 1C 1831 Diegem - Belgia
English: 65926 Frankfurt am Main, Deutschland
Estonian: 65926 Frankfurt am Main, Saksamaa
English: Sweden sanofi-aventis AB Box 141 42
Estonian: Rootsi sanofi-aventis AB Box 141 42
English: United Kingdom Aventis Pharma Limited,
Estonian: Ühendkuningriik Aventis Pharma Limited,
English: Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Cyprus
Estonian: Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Küpros
English: Greece sanofi-aventis AEBE 348 Syngrou avenueBuilding A
Estonian: Kreeka sanofi-aventis AEBE 348 Syngrou avenueBuilding A
English: Estonia sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Estonia
Estonian: Eesti sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Eesti
English: Ireland sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Ireland
Estonian: Iirimaa sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Iirimaa
English: UAB “SANOFIAVENTIS LIETUVA”, A.Juozapavičiaus g. 6/2, LT-09310 Vilnius, Lithuania
Estonian: UAB “SANOFIAVENTIS LIETUVA”, A.Juozapavičiaus g. 6/2, LT-09310 Vilnius, Leedu
English: United Kingdom Aventis Pharma Limited, 50 Kings Hill Avenue
Estonian: Ühendkuningriik Aventis Pharma Limited, 50 Kings Hill Avenue
English: Sanofi-Avenstis Bulgaria EOOD, Bulgaria, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8
Estonian: Sanofi-Avenstis Bulgaria EOOD, Bulgaaria, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8
English: Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS, United Kingdom)
Estonian: Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS,
English: Hungary sanofi-aventis Zrt.
Estonian: Ungari sanofi-aventis Zrt.
English: Netherlands sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, The Netherlands
Estonian: Holland sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, Holland
English: Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Germany
Estonian: Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Saksamaa
English: Bratislava, Slovak Republic
Estonian: Ljubljana, Sloveenia
English: Finland sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Finland
Estonian: Soome sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Soome
English: Italy sanofi-aventis S.p.A. Viale Luigi Bodio 37/B 20158 Milan Italy
Estonian: Viale Luigi Bodio 37/B 20158 Milan Itaalia
English: Slovenia sanofi-aventis d.o.o, Dunajska 151, 1000 Ljubljana, Slovenia
Estonian: Sloveenia sanofi-aventis d.o.o, Dunajska 151, 1000
English: Czech Republic sanofi-aventis, s.r.o.
Estonian: Tsehhi sanofi-aventis, s.r.o.
English: Luxembourg Sanofi-aventis Belgium
Estonian: Luksemburg Sanofi-aventis Belgium
English: Belgium Sanofi-aventis Belgium
Estonian: Sanofi-aventis Belgium
English: Sanofi-aventis France 1-13 Boulevard Romain Rolland 75014 Paris FRANCE
Estonian: Prantsusmaa Sanofi-aventis France 1-13 Boulevard
English: Tavanic 500 500 mg Film-coated tablets
Estonian: Tavanic 500 500 mg Film-coated tablet Suukaudne
English: Zurampic lesinurad
Estonian: Zurampic lesinuraad
English: Patients should drink plenty of fluids throughout the day.
Estonian: Patsient peab kogu päeva jooksul tarbima palju vedelikku.
English: The full EPAR and risk management plan summary for Zurampic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Zurampicu kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Zurampic is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Zurampicu võimalikult ohutu kasutamine.
English: What is Zurampic and what is it used for?
Estonian: Mis on Zurampic ja milleks seda kasutatakse?
English: What measures are being taken to ensure the safe and effective use of Zurampic?
Estonian: Mis meetmed võetakse, et tagada Zurampicu ohutu ja efektiivne kasutamine?
English: Other information about Zurampic
Estonian: Muu teave Zurampicu kohta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zurampic's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Zurampicu kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Zurampic is available as 200-mg tablets.
Estonian: Zurampicut turustatakse 200 mg tablettidena.
English: Zurampic was studied in two main studies involving over 1,200 adults with gout who were previously treated with allopurinol.
Estonian: Korraldati kaks Zurampicu põhiuuringut, milles osales üle 1200 podagraga täiskasvanu, keda enne raviti allopurinooliga.
English: Why is Zurampic approved?
Estonian: Miks Zurampic heaks kiideti?
English: Zurampic contains the active substance lesinurad.
Estonian: Zurampic sisaldab toimeainet lesinuraadi.
English: This summary was last updated in 02-2016.
Estonian: Kokkuvõtte viimane uuendus: KK-2016.
English: A third main study involved 324 adults who had at least one measurable tophus (large deposit of uric acid in or around a joint or under the skin) and with high blood levels of uric acid (over 80 mg/litre without gout medicines or above 60 mg/litre despite treatment with allopurinol or febuxostat).
Estonian: Kolmandas põhiuuringus osales 324 patsienti, kellel oli vähemalt üks mõõdetav toofus (laialdane kusihappeladestus liigeses või liigese ümber naha all) ja suur vere kusihappesisaldus (üle 80 mg/l ilma podagraravimiteta või üle 60 mg/l vaatamata allopurinool- või febuksostaatravile).
English: The most serious adverse reactions were kidney failure, reduced kidney function, and kidney stones, which affected less than 1 patient in 100.
Estonian: Kõige raskemad kõrvalnähud olid neerupuudulikkus, neerufunktsiooni halvenemine ja neerukivid, mis esinesid vähem kui 1 patsiendil 100st.
English: It is not intended to provide practical advice on how to use Zurampic.
Estonian: Hindamisaruandes ei anta Zurampicu kasutamise praktilisi nõuandeid.
English: These studies compared the effect of adding Zurampic or placebo (a dummy treatment) to patients' allopurinol treatment.
Estonian: Uuringutes võrreldi Zurampicu või platseebo (näiva ravimi) lisamist patsientide allopurinoolravile.
English: Patients were first treated with febuxostat alone for three weeks and then with febuxostat plus either Zurampic or placebo.
Estonian: Esialgu raviti patsiente kolm nädalat ainult febuksostaadiga, seejärel febuksostaadi ja Zurampicu või platseeboga.
English: Risks such as kidney damage or heart problems are addressed in the product information.
Estonian: Riske, nagu neerukahjustus ja südameprobleemid, on täpsemalt kirjeldatud pakendi infolehel.
English: Their blood level of uric acid was not sufficiently controlled with allopurinol alone and was above 60 mg/litre at the start of the study.
Estonian: Nende vere kusihappesisaldus ei olnud üksnes allopurinooliga piisavalt reguleeritud ja see ületas uuringu algul 60 mg/l.
English: Patients must not take Zurampic if they suffer from tumour lysis syndrome (a complication due to the rapid breakdown of cancer cells during cancer treatment) or a rare hereditary disease called LeschNyhan syndrome, both of which raise uric acid levels in the blood.
Estonian: Patsiendid ei tohi võtta Zurampicut, kui neil esineb tuumori lüüsi sündroom (vähiraviaegne vähirakkude kiirest lagunemisest tingitud tüsistus) või haruldane pärilik haigus Lesch-Nyhani sündroom, mis mõlemad suurendavad vere kusihappesisaldust.
English: What are the risks associated with Zurampic?
Estonian: Mis riskid Zurampicuga kaasnevad?
English: The most common side effects with Zurampic (which may affect up to 1 in 10 people) are flu, headache, heartburn and (gastro-oesophageal reflux disease) stomach acid coming back to the mouth, and blood tests showing increased blood creatinine levels (a marker of kidney function).
Estonian: Zurampicu kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on gripp, peavalu, kõrvetised ja maohappe tagasivool suhu (gastroösofageaalne reflukshaigus) ning vereanalüüsides kreatiniinisisalduse suurenemine (neerufunktsiooni näitaja).
English: The recommended dose is 200 mg once daily, taken in the morning at the same time as a xanthine oxidase inhibitor medicine such as allopurinol or febuxostat.
Estonian: Soovitatav annus on 200 mg üks kord ööpäevas hommikuti samal ajal koos ksantiini oksüdaasi inhibiitorit sisaldava ravimi, näiteks allopurinooli või febuksostaadiga.
English: This is a summary of the European public assessment report (EPAR) for Zurampic.
Estonian: See on ravimi Zurampic Euroopa avaliku hindamisaruande kokkuvõte.
English: If treatment with the xanthine oxidase inhibitor is interrupted, then treatment with Zurampic must also be interrupted at the same time.
Estonian: Kui ravi ksantiini oksüdaasi inhibiitoriga katkestatakse, tuleb samal ajal katkestada ka ravi Zurampicuga.
English: Looking just at patients whose blood uric acid level did not fall sufficiently on treatment with febuxostat alone, the level dropped to less than 50 mg/litre in 44% (26 of 59) patients taking Zurampic compared to 24% (12 of 51) patients taking placebo.
Estonian: Nendest patsientidest, kelle vere kusihappesisaldus ainult febuksostaatraviga ei vähenenud, langes kusihappesisaldus alla 50 mg/l 44%-l Zurampicut tarvitanud patsientidest (26 patsienti 59st) ja 24%-l platseebopatsientidest (12 patsienti 51st).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zurampic, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Zurampicu omaduste kokkuvõttesse ja pakendi infolehele ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Over time, visible deposits of uric acid disappeared in increasing number of patients continuing Zurampic and febuxostat treatment, and fewer patients had recurrence of gout attacks.
Estonian: Aja jooksul kadusid nähtavad kusihappeladestused üha suuremal arvul patsientidel, kes jätkasid ravi Zurampicu ja febuksostaadiga, ning ägedaid podagraatakke esines väiksemal hulgal patsientidel.
English: The company that markets Zurampic will carry out a study on the risk of heart, circulation or kidney disorders in patients treated with Zurampic, particularly in those who have previously suffered from such disorders.
Estonian: Zurampicut turustaja korraldab uuringu, et hinnata südame-, veresoonkonna- ja neeruhaiguste tekke riski Zurampicuga ravitud patsientidel, eriti neil, kes on juba varem selliseid haigusi põdenud, sest Zurampicu-ravi ajal on neid haigusi esinenud.
English: How is Zurampic used?
Estonian: Kuidas Zurampicut kasutatakse?
English: This prevents the build-up of uric acid in joints where it can cause pain, swelling and joint damage.
Estonian: See takistab kusihappe ladestumist liigestes, kus see põhjustab valu, turset ja liigesekahjustusi.
English: For practical information about using Zurampic, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Zurampicu kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Zurampic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zurampicuga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: By blocking URAT1, more uric acid is passed out in the urine and less remains in the blood.
Estonian: URAT1 blokeerimisega viiakse uriiniga rohkem kusihapet välja ja seega väheneb vere kusihappesisaldus.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zurampic on 18 February 2016.
Estonian: Euroopa Komisjon andis Zurampicu müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, <müügiloa väljastamise kuupäev>.
English: Zurampic is used in combination with a xanthine oxidase inhibitor such as allopurinol or febuxostat.
Estonian: Zurampicut kasutatakse koos ksantiini oksüdaasi inhibiitoriga, näiteks allopurinooli või febuksostaadiga.
English: Gout results from a build-up of uric acid crystals in and around the joints, especially in the toes, which causes pain and swelling.
Estonian: Podagra tekib kusihappekristallide ladestumisel liigestes ja liigeste ümber, eriti varvastes, põhjustades turset ja valu.
English: The patient's kidney function will be monitored regularly during treatment with Zurampic and the doctor will advise the patient to take sufficient fluid during the day and always take Zurampic with either allopurinol or febuxostat, which helps to prevent kidney damage from Zurampic.
Estonian: Arst soovitab patsiendil tarvitada päeva jooksul piisavalt vedelikku ja võtta Zurampicut alati koos allopurinooli või febuksostaadiga, sest see aitab ennetada Zurampicu kahjulikku toimet neerudele.
English: What benefits of Zurampic have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zurampicu kasulikkus?
English: Patients with very poor kidney function or who have had a kidney transplant must also not take Zurampic.
Estonian: Ka neerufunktsiooni olulise halvenemise ja siiratud neeruga patsiendid ei tohi Zurampicut kasutada.
English: Overall, Zurampic 200 mg once daily was effective in 57% (60 of 106) patients.
Estonian: Kokkuvõttes oli üks kord ööpäevas lisatud 200 mg Zurampic efektiivne 57%-l patsientidest (60 patsienti 106st) ning 47%-l platseeborühma patsientidest (51 patsienti 109st).
English: Xanthine oxidase inhibitors reduce the production of uric acid in the body.
Estonian: Ksantiini oksüdaasi inhibiitorid vähendavad kusihappe teket organismis.
English: The main measure of effectiveness was the number of patients whose blood level of uric acid dropped below 60 mg/litre after 6 months of treatment.
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kelle vere kusihappesisaldus oli pärast 6 ravikuud alla 60 mg/l.
English: For the full list of all side effects reported with Zurampic, see the package leaflet.
Estonian: Zurampicu kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The medicine can only be obtained with a prescription.
Estonian: Zurampic on retseptiravim.
English: The main measure of effectiveness was the number of patients whose blood level of uric acid dropped below 50 mg/litre after 6 months of treatment.
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kelle vere kusihappesisaldus oli pärast 6 ravikuud alla 50 mg/l.
English: Combined with a xanthine oxidase inhibitor, Zurampic reduced blood levels of uric acid in patients with gout whose high uric acid levels were not sufficiently controlled by a xanthine oxidase inhibitor.
Estonian: Koos ksantiini oksüdaasi inhibiitoriga kasutamisel vähendas Zurampic vere kusihappesisaldust podagrapatsientidel, kelle vere suurt kusihappesisaldust ei suudetud ksantiini oksüdaasi inhibiitoriga piisavalt reguleerida.